Rhythm Biosciences (RHY) Stock Overview
A medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RHY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Rhythm Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.095 |
| 52 Week High | AU$0.21 |
| 52 Week Low | AU$0.047 |
| Beta | 0.35 |
| 1 Month Change | 10.47% |
| 3 Month Change | 11.76% |
| 1 Year Change | 14.46% |
| 3 Year Change | -90.87% |
| 5 Year Change | -88.41% |
| Change since IPO | -70.77% |
Recent News & Updates
Recent updates
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?
Dec 06
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate
Aug 09We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Apr 11Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Dec 02We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Jul 19Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Mar 03Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?
Dec 03Shareholder Returns
| RHY | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | 20.3% | 1.0% | 0.6% |
| 1Y | 14.5% | -12.6% | 4.7% |
Return vs Industry: RHY exceeded the Australian Healthcare industry which returned -12.6% over the past year.
Return vs Market: RHY exceeded the Australian Market which returned 4.7% over the past year.
Price Volatility
| RHY volatility | |
|---|---|
| RHY Average Weekly Movement | 12.2% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 18.5% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: RHY has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: RHY's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Atkins | rhythmbio.com |
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Rhythm Biosciences Limited Fundamentals Summary
| RHY fundamental statistics | |
|---|---|
| Market cap | AU$30.98m |
| Earnings (TTM) | -AU$3.83m |
| Revenue (TTM) | AU$3.19m |
Is RHY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHY income statement (TTM) | |
|---|---|
| Revenue | AU$3.19m |
| Cost of Revenue | AU$224.89k |
| Gross Profit | AU$2.97m |
| Other Expenses | AU$6.80m |
| Earnings | -AU$3.83m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 92.95% |
| Net Profit Margin | -119.97% |
| Debt/Equity Ratio | 151.5% |
How did RHY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 01:08 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rhythm Biosciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stuart Roberts | Pitt Street Research Pty Ltd. |